AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by equities researchers at Deutsche Bank AG in a report released on Friday. They currently have a GBX 6,200 ($77.46) target price on the biopharmaceutical company’s stock. Deutsche Bank AG’s price objective would suggest a potential upside of 42.02% from the company’s previous close.

Other analysts also recently issued research reports about the company. Citigroup Inc. restated a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday, July 27th. Bryan, Garnier & Co reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Thursday, July 28th. BNP Paribas set a GBX 5,300 ($66.22) price target on AstraZeneca plc and gave the company a “buy” rating in a report on Tuesday, August 2nd. Berenberg Bank upped their price target on AstraZeneca plc from GBX 5,400 ($67.47) to GBX 5,600 ($69.97) and gave the company a “buy” rating in a report on Thursday, August 11th. Finally, Societe Generale set a GBX 7,000 ($87.46) price target on AstraZeneca plc and gave the company a “buy” rating in a report on Thursday, September 8th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 4,947.72 ($61.82).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 4343.00 on Friday. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The firm’s 50-day moving average price is GBX 4,806.39 and its 200-day moving average price is GBX 4,565.34. The firm’s market cap is GBX 54.94 billion.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.